X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PIRAMAL ENTERPRISES ELDER PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -0.2 36.6 - View Chart
P/BV x 0.1 3.0 3.3% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PIRAMAL ENTERPRISES
Mar-17
ELDER PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3802,095 18.1%   
Low Rs1881,025 18.3%   
Sales per share (Unadj.) Rs491.2492.8 99.7%  
Earnings per share (Unadj.) Rs-3.272.6 -4.4%  
Cash flow per share (Unadj.) Rs14.494.7 15.2%  
Dividends per share (Unadj.) Rs021.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5862.5 43.7%  
Shares outstanding (eoy) m20.54172.56 11.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.2 18.3%   
Avg P/E ratio x-89.321.5 -415.2%  
P/CF ratio (eoy) x19.716.5 119.6%  
Price / Book Value ratio x0.81.8 41.7%  
Dividend payout %028.9 0.0%   
Avg Mkt Cap Rs m5,833269,194 2.2%   
No. of employees `000NA4.0 0.0%   
Total wages/salary Rs m2,17917,939 12.1%   
Avg. sales/employee Rs ThNM21,190.3-  
Avg. wages/employee Rs ThNM4,470.1-  
Avg. net profit/employee Rs ThNM3,120.0-  
INCOME DATA
Net Sales Rs m10,08985,037 11.9%  
Other income Rs m2572,338 11.0%   
Total revenues Rs m10,34687,374 11.8%   
Gross profit Rs m-79234,991 -2.3%  
Depreciation Rs m3613,817 9.5%   
Interest Rs m2,75620,310 13.6%   
Profit before tax Rs m-3,65313,202 -27.7%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,713-100 -3,731.4%   
Tax Rs m1252,281 5.5%   
Profit after tax Rs m-6512,520 -0.5%  
Gross profit margin %-7.841.1 -19.1%  
Effective tax rate %-3.417.3 -19.8%   
Net profit margin %-0.614.7 -4.4%  
BALANCE SHEET DATA
Current assets Rs m9,24087,590 10.5%   
Current liabilities Rs m9,998185,578 5.4%   
Net working cap to sales %-7.5-115.2 6.5%  
Current ratio x0.90.5 195.8%  
Inventory Days Days4631 149.2%  
Debtors Days Days6048 126.1%  
Net fixed assets Rs m10,124108,523 9.3%   
Share capital Rs m206345 59.6%   
"Free" reserves Rs m5,582148,481 3.8%   
Net worth Rs m7,734148,826 5.2%   
Long term debt Rs m4,889144,957 3.4%   
Total assets Rs m22,882482,394 4.7%  
Interest coverage x-0.31.7 -19.7%   
Debt to equity ratio x0.61.0 64.9%  
Sales to assets ratio x0.40.2 250.1%   
Return on assets %11.86.8 172.8%  
Return on equity %-0.88.4 -10.0%  
Return on capital %22.312.0 186.7%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30715,001 2.0%   
Fx outflow Rs m1255,150 2.4%   
Net fx Rs m1819,851 1.8%   
CASH FLOW
From Operations Rs m11,754-100,393 -11.7%  
From Investments Rs m-561-24,202 2.3%  
From Financial Activity Rs m-6,762135,705 -5.0%  
Net Cashflow Rs m4,43211,110 39.9%  

Share Holding

Indian Promoters % 39.6 52.9 74.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 4.0 187.5%  
FIIs % 16.8 26.6 63.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 16.5 218.8%  
Shareholders   16,479 93,274 17.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   DISHMAN PHARMA  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong US Markets; SBI, Tata Steel & Other Top Cues to Sway the Markets Today(Pre-Open)

After opening the day in green, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS